Eric Coleman
Examiner (ID: 5943, Phone: (571)272-4163 , Office: P/2183 )
Most Active Art Unit | 2183 |
Art Unit(s) | 2183, 2783, 2302 |
Total Applications | 2373 |
Issued Applications | 2061 |
Pending Applications | 80 |
Abandoned Applications | 232 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18893673
[patent_doc_number] => 20240009158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => METHODS FOR TREATING ALLAN-HERNDON-DUDLEY SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/350116
[patent_app_country] => US
[patent_app_date] => 2023-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4457
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18350116
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/350116 | METHODS FOR TREATING ALLAN-HERNDON-DUDLEY SYNDROME | Jul 10, 2023 | Pending |
Array
(
[id] => 18806830
[patent_doc_number] => 20230381163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => DABIGATRAN COMPOSITIONS AND METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION
[patent_app_type] => utility
[patent_app_number] => 18/323382
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15040
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18323382
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/323382 | DABIGATRAN COMPOSITIONS AND METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION | May 23, 2023 | Pending |
Array
(
[id] => 18806812
[patent_doc_number] => 20230381145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/304263
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5334
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304263
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/304263 | OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND METHODS | Apr 19, 2023 | Pending |
Array
(
[id] => 18451373
[patent_doc_number] => 20230192651
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => Pyrrolidine Derivative and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 18/080732
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080732
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/080732 | Pyrrolidine Derivative and Use Thereof | Dec 12, 2022 | Pending |
Array
(
[id] => 18346822
[patent_doc_number] => 20230134932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => EIF4E INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/822337
[patent_app_country] => US
[patent_app_date] => 2022-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/822337 | EIF4E INHIBITORS AND USES THEREOF | Aug 24, 2022 | Pending |
Array
(
[id] => 18284895
[patent_doc_number] => 20230100367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/894333
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894333
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894333 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | Aug 23, 2022 | Pending |
Array
(
[id] => 18064412
[patent_doc_number] => 20220395499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
[patent_app_type] => utility
[patent_app_number] => 17/833829
[patent_app_country] => US
[patent_app_date] => 2022-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17833829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/833829 | CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION | Jun 5, 2022 | Pending |
Array
(
[id] => 18020495
[patent_doc_number] => 20220371994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => CRYSTALLINE POLYMORPHIC FORM OF PSILOCIN
[patent_app_type] => utility
[patent_app_number] => 17/737543
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737543
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737543 | CRYSTALLINE POLYMORPHIC FORM OF PSILOCIN | May 4, 2022 | Pending |
Array
(
[id] => 17141645
[patent_doc_number] => 20210309657
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/331598
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16169
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17331598
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/331598 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | May 25, 2021 | Pending |
Array
(
[id] => 17052100
[patent_doc_number] => 20210261534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => SELECTIVE ESTROGEN RECEPTOR DEGRADER
[patent_app_type] => utility
[patent_app_number] => 17/308501
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308501
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308501 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | May 4, 2021 | Pending |
Array
(
[id] => 17049816
[patent_doc_number] => 20210259250
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => COMPOSITION, SPRAY, AND WIPER
[patent_app_type] => utility
[patent_app_number] => 17/244304
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17547
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244304
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/244304 | COMPOSITION, SPRAY, AND WIPER | Apr 28, 2021 | Pending |
Array
(
[id] => 17020865
[patent_doc_number] => 20210244736
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
[patent_app_type] => utility
[patent_app_number] => 17/232383
[patent_app_country] => US
[patent_app_date] => 2021-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17232383
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/232383 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | Apr 15, 2021 | Pending |
Array
(
[id] => 16977595
[patent_doc_number] => 20210221832
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/213125
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25559
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213125
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213125 | SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | Mar 24, 2021 | Pending |
Array
(
[id] => 16962818
[patent_doc_number] => 20210214317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/212806
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212806
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212806 | PYRIMIDINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | Mar 24, 2021 | Pending |
Array
(
[id] => 17546623
[patent_doc_number] => 20220117964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => COMBINATION OF FAK INHIBITOR AND BTK INHIBITOR FOR TREATING A DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/413319
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413319
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/413319 | COMBINATION OF FAK INHIBITOR AND BTK INHIBITOR FOR TREATING A DISEASE | Jun 23, 2020 | Pending |
Array
(
[id] => 17505101
[patent_doc_number] => 20220098203
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/418406
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418406
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/418406 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Dec 26, 2019 | Pending |
Array
(
[id] => 17561639
[patent_doc_number] => 20220125788
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => FAK inhibitor and drug combination thereof
[patent_app_type] => utility
[patent_app_number] => 17/418678
[patent_app_country] => US
[patent_app_date] => 2019-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8618
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 184
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/418678 | FAK inhibitor and drug combination thereof | Dec 23, 2019 | Pending |
Array
(
[id] => 17426737
[patent_doc_number] => 20220054445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/414399
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22530
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17414399
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/414399 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | Dec 19, 2019 | Pending |
Array
(
[id] => 17458681
[patent_doc_number] => 20220071985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/416679
[patent_app_country] => US
[patent_app_date] => 2019-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25434
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 216
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416679
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/416679 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | Dec 18, 2019 | Pending |
Array
(
[id] => 17312762
[patent_doc_number] => 20210401810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses
[patent_app_type] => utility
[patent_app_number] => 17/294762
[patent_app_country] => US
[patent_app_date] => 2019-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12348
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294762
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/294762 | Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses | Nov 26, 2019 | Pending |